{'fraction_non_alphanumeric': 0.034722222222222224, 'fraction_numerical': 0.006944444444444444, 'mean_word_length': 5.865079365079365, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Stimulation of ADAM10 and decrease in plaques by a sleep‐inducing supplement

One of the pathologic hallmarks of Alzheimer’s disease (AD) is the presence of extracellular amyloid plaques containing Aβ peptides, which originate from the amyloidogenic proteolytic processing of amyloid precursor protein (APP), through the sequential action of β‐ and γ‐secretases. On the other hand, APP can also be cleaved by a non‐amyloidogenic pathway by α‐secretase “a disintegrin and metalloproteinase” 10 (ADAM10), precluding the formation of Aβ peptides. Therefore, delineating drugs and pathways for stimulating non‐amyloidogenic metabolism of APP and lowering plaques is an important area of research. We have seen that oleamide, a sleep‐inducing supplement in human, is present in hippocampal nuclei as a ligand of peroxisome proliferator‐activated receptor alpha (PPARα).